Tantti Laboratory Inc. (“Tantti”) was founded in 2014 by eight distinguished professors in Taiwan with expertise in Chemical and Materials Engineering. Since its inception, the company has developed two platform technologies (Tantti® Monolith and Tantti® BioScaffolds) which use in-mold polymerization and microfluidics to create highly ordered micro- and nano-porous biomaterials.
▪Tantti® DuloCore™ represents a breakthrough in liquid chromatographic technology used in the separation and purification of large biomolecules, including DNA plasmids, mRNA, viral vectors, viruses and exosomes. Its applications target downstream process (DSP) of biopharma products in advanced therapies and vaccines.
▪Tantti® BioScaffolds, which include our UniTantrix™ Microcarriers and 3D BioScaffold product lines, are our platform solution for the biomedical industry’s growing needs for high-density cell expansion used in vaccine/viral particle production, cell therapy, tissue engineering, regenerative medicine, and high-throughput/content drug screening, among other applications.
Our technologies have received patent approvals around the world, including in the United States, Europe, Japan, Taiwan and China, and we continue to conduct extensive R&D in-house as well as with our academic and corporate research partners.
At Tantti, our mission is not only to develop innovative biomaterial technologies that provide the highest performing, cost- and time-effective solutions for our customers. We also aim to become a collaborative partner with our customers, assisting them in realizing their visions of developing innovative biologic products for advanced therapies, whether it is in a small-scale research setting or at the commercial production stage. We distribute our products around the world, both directly to customers and through our distribution partners.
Ultimately, we hope our commitment to innovation, quality, and service will drive Tantti’s long-term sustainable growth in the biomaterials industry. Together with our partners, we strive to become a world-class, global biomaterials company and we sincerely welcome you to collaborate with us, whether as a customer, distributor, research partner, employee or as an investor/shareholder.
Tantti Quality Policy
We are committed to providing our customers with high-quality and innovative products that meet their expectations as well as regulatory requirements.
He was a National Endowed Chair Professor (2006-2009) as well as President of NCHU (2001).
Dr. Hsiue is a recipient of the Lifetime Achievement Award from the Polymer Society of Taiwan (2005) as well as the Scientific Achievement Award from the Japanese Biomaterials Society (2012).
At CYCU, he is the founder of the R&D Center for Membrane Technology (2000).
He is also a National Endowed Chair Professor (2014).
He was also previously the CEO for Chip Power Technology Corp.
Dr. Hu earned his Ph.D. in Material Science and Engineering from the Massachusetts Institute of Technology(MIT).
Prior to Tantti, he was with the Institute for Information Industry and with Datatrans System Inc.
Dr. Lee earned his Ph.D. in Computer Science and Information Engineering from National Central University in Taiwan.
Prior to Tantti, Dr. Chen was a Professor of Chemical and Materials Engineering at National Central University in Taiwan.
Dr. Chen earned his Ph.D. in Polymer Chemistry from the Tokyo Institute of Technology.
Dr. Lin earned his Ph.D. in Material Science and Engineering from the University of California, Los Angeles (UCLA)
Investment Manager of Taiwan Biotech Co. Ltd. before founding Tantti Lab.
Specializes in drug development, GMP and ISO.
Notable clients included DuPont, Mitsubishi Chemical, Wyeth, Sinopec, among others.
Formerly with Goldman Sachs, Evercore, Credit Suisse and Houlihan Lokey.